Our result will contribute to the literature that the use of trastuzumab, apart from its established efficacy to ameliorate the disease-free survival, is associated with reduced locoregional events in patients with stage II/III HER2+ breast cancer receiving comprehensive local-regional therapy. This evidence concerns the gene ERBB2 and breast carcinoma.